Literature DB >> 3362273

Red cell alloimmunization in chronic renal failure patients undergoing hemodialysis.

R E Domen1, G Ramirez.   

Abstract

Posttransfusion alloimmunization to red cell antigens was studied in a group of 98 chronic renal disease patients treated solely with hemodialysis. Clinically significant red cell antibodies were formed in only 6.1% of transfused patients, and only 1 patient formed more than one antibody. We do not recommend extended red cell phenotyping, beyond ABO and Rh(D), in patients with end-stage renal disease who may require transfusion.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3362273     DOI： 10.1159/000184943

Source DB:  PubMed          Journal:  Nephron        ISSN： 1660-8151            Impact factor:   2.847


  6 in total

1.  Frequency of alloantibodies among chronic renal failure patients in red sea state.

Authors:  Hythum Abdullah M Babiker; Tagwa Yousif Elsayed
Journal:  Indian J Hematol Blood Transfus       Date:  2013-02-12       Impact factor: 0.900

Review 2.  Red blood cell transfusion risks in patients with end-stage renal disease.

Authors:  Yvette C Tanhehco; Jeffrey S Berns
Journal:  Semin Dial       Date:  2012-06-11       Impact factor: 3.455

3.  Red cell alloimmunization in multitransfused patients and multiparous women.

Authors:  Jalada Patel; Rinku Shukla; Snehalata Gupte
Journal:  Indian J Hematol Blood Transfus       Date:  2009-07-05       Impact factor: 0.900

4.  Detection of alloimmunization to ensure safer transfusion practice.

Authors:  Rashmi Sood; R N Makroo; Vimarsh Riana; N L Rosamma
Journal:  Asian J Transfus Sci       Date:  2013-07

5.  Antibody screening & identification in the general patient population at a tertiary care hospital in New Delhi, India.

Authors:  Raj Nath Makroo; Aakanksha Bhatia; Vikas Hegde; Mohit Chowdhry; Uday Kumar Thakur; N L Rosamma
Journal:  Indian J Med Res       Date:  2014-09       Impact factor: 2.375

6.  Association between renal failure and red blood cell alloimmunization among newly transfused patients.

Authors:  Josine A Oud; Dorothea Evers; Rutger A Middelburg; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Johanna G van der Bom; Jaap Jan Zwaginga
Journal:  Transfusion       Date:  2020-12-09       Impact factor: 3.337
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.